AUTOIMMUNE DISEASES INVOLVING THE NOSE, ORAL CAVITY, AND SKIN: A CRITICAL ENT-DERMATOLOGIC REVIEW
Keywords:
Systemic lupus erythematosus; Dermatomyositis; Sjögren’s syndrome; Pemphigus vulgaris; Mucous membrane pemphigoidAbstract
DOI: https://doi.org/10.46296/gt.v9i17.0340
Abstract
Systemic autoimmune diseases often present with skin and mucosal lesions in the nasal or oral cavity that may precede or reflect overall disease activity. This article provides a critical review of five key entities: systemic lupus erythematosus, dermatomyositis, Sjögren’s syndrome, pemphigus (vulgaris and foliaceus), and mucous membrane pemphigoid. We examine their otorhinolaryngologic and dermatologic manifestations, highlighting clinicopathologic correlations between cutaneous and mucosal lesions as markers of systemic disease activity. We also discuss prognostic factors according to dermatologic patterns – for example, extensive mucosal involvement associated with more severe disease – and the importance of combined skin and mucosal biopsy for early definitive diagnosis. Current recommendations for multidisciplinary management and recent therapeutic advances (such as biologic therapy in pemphigus) that have improved outcomes are included. This review, grounded in literature from the past decade, emphasizes the need for a combined dermatology–rheumatology–ENT approach to optimize the detection and treatment of these uncommon but potentially severe diseases.
Keywords: Systemic lupus erythematosus; Dermatomyositis; Sjögren’s syndrome; Pemphigus vulgaris; Mucous membrane pemphigoid.
Downloads
References
Lerner G, Jeremias P, Matthias T. The world incidence and prevalence of autoimmune diseases is increasing. Int J Celiac Dis. 2015;3(4):151–155.
Saccucci M, Di Carlo G, Bossù M, et al. Autoimmune diseases and their manifestations on oral cavity: diagnosis and clinical management. J Immunol Res. 2018;2018:6061825【PMCID: PMC5994274】.
Du F, Qian W, Zhang X, et al. Prevalence of oral mucosal lesions in patients with systemic lupus erythematosus: a systematic review and meta-analysis. BMC Oral Health. 2023;23(1):1030【PMCID: PMC10734171】.
Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(9):1400–1412.
Alimohammadi R, Ramezani M, Jafarzadeh A. A case report with perforation of nasal septum and palate due to systemic lupus erythematosus. Autoimmune Dis. 2023; (Article ID 667852).
Castillo JSS, Callen JP, Vleugels RA. Covert clues: the non-hallmark cutaneous manifestations of dermatomyositis. Ann Transl Med. 2021;9(5):434.
Milani-Nejad N, Werth VP, Franks AG. Gingival telangiectasia of dermatomyositis. Br J Dermatol. 2020;183(4):e93.
Vivino FB. Sjögren syndrome clinical presentation (Dry nose and sinuses). In: Medscape Drugs & Diseases [Internet]. Updated Jan 2023.
Graf S, Kirschstein L, Adamietz IA, et al. Systematic evaluation of laryngeal impairment in Sjögren’s syndrome. Eur Arch Otorhinolaryngol. 2021;278(7):2421–2428.
Hwang JCH, Gill AS, Squires LD, Steele TO. Sjögren’s syndrome sequelae: nasal synechiae and nasopharyngeal stenosis (case report). Ear Nose Throat J. 2021;100(10_suppl):1095S–1097S.
Breillat P, Pérez-Fernández OM, Ng WF, et al. Cutaneous vasculitis in primary Sjögren disease. JAMA Dermatol. 2025;161(1):e252665.
Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjögren’s syndrome and related therapeutic perspectives. Rheumatology (Oxford). 2020;59(6):S17–S27.
Marinović B, Miše J, Bukvić Mokos Z. Pemphigus – the crux of clinics, research, and treatment during the COVID-19 pandemic. Biomedicines. 2021;9(11):1555.
Stanikova L, Formanek M, Kominek P, Zelenik K. Diagnosis of laryngeal pemphigus vulgaris can be facilitated using advanced endoscopic methods. Medicina (Kaunas). 2021;57(7):686.
Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunol Res. 2018;66(2):255–270.
Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for moderate to severe pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031–2040.
Davis G, Hathway R, Shipley D, Staines K. Management of pemphigus vulgaris and mucous membrane pemphigoid in a combined oral medicine and dermatology clinic: a five-year narrative review. Br Dent J. 2024;236:311–316.
Galperín GD, Candiz ME, Forero OL, et al. Penfigoide de las membranas mucosas: revisión de conceptos y consenso terapéutico intersocietario. Oftalmol Clín Exp. 2023;16(S2):1–54.
Treister N, Bruch JM. Oral mucosal lesions, immunologic diseases. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
Sociedad Argentina de Dermatología. Guías de Manejo de los Pénfigos (Consenso 2020). Rev. Argent. Dermatol. 2020;101(Supl. 1):7–42.
Published
How to Cite
Issue
Section
Copyright (c) 2026 GESTAR Arbitrated Scientific Journal in Health Research. ISSN: 2737-6273.

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
















